key: cord-0808309-62kvrryg authors: Bjork, J.; Bonander, C.; Moghaddassi, M.; Rasmussen, M.; Malmqvist, U.; Inghammar, M.; Kahn, F. title: COVID-19 vaccine effectiveness against severe disease from the Omicron BA.1 and BA.2 subvariants: surveillance results from southern Sweden, December 2021 to March 2022 date: 2022-04-18 journal: nan DOI: 10.1101/2022.04.14.22273896 sha: e4d05d15fc788158a05b0337395ceb1b7426f1e6 doc_id: 808309 cord_uid: 62kvrryg We compared vaccine effectiveness (VE) against severe COVID-19 during calendar periods from December 2021 to March 2022 when Omicron BA.1 and BA.2, respectively, were the dominating virus variants in Scania county, Sweden. We used continuous density case-control sampling matched for sex and age, and with further adjustment for differences in comorbidities and prior infection. VE remained relatively stable after the transition from BA.1 to BA.2 among people with at least three doses but decreased markedly among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. These findings suggest that booster vaccination is needed to maintain sufficient protection against severe COVID-19. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) Omicron (Phylogenetic Assignment of Named Global Outbreak (Pango) lineage designation B.1.1.529) has two genetically divergent subvariants, BA.1 and BA.2. A comparison of secondary attack rates from Denmark suggests that the subvariant BA.2 carries a transmission advantage compared to BA.1 (1) , which may explain why BA.2 has rapidly replaced BA.1 as the dominant subvariant in several countries. A study from UK suggests similar vaccine protection against symptomatic disease from BA.2 as for BA.1 (2) . However, few studies have compared the protection against severe disease from these two Omicron subvariants. Recent findings from Qatar suggested lower vaccine protection against hospitalizations and deaths from BA.2 but with a very wide confidence interval (3) . The aim of the present study was to compare COVID-19 vaccine effectiveness against severe disease from the Omicron BA.1 and BA.2 subvariants. The study was conducted in Scania county, southern Sweden, one of the first regions in the world where BA.2 became dominant. The study cohort included all persons residing in Scania county (Skåne), southern Sweden, on 27 December 2020 (baseline) when vaccinations started (n = 1,384,531) (4, 5) and were followed longitudinally for positive SARS-CoV-2 tests, hospitalisations and assessment of disease severity. Individuals who died or moved away from the region were censored on the date of death or relocation. In the present study we used data from routine sequencing of samples of infected cases in Scania county to compare vaccine effectiveness during three specific calendar periods (Supplementary Table S1 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 18, 2022. ; https://doi.org/10.1101/2022.04.14.22273896 doi: medRxiv preprint Data from national and regional register holders were linked using the personal identification number assigned to all Swedish residents. Weekly updates on vaccination date, type of vaccine and dose were obtained from the National Vaccination Register, and data on COVID-19 cases (defined by a positive SARS-CoV-2 test results) from the electronic system SMINet, both kept at the Public Health Agency of Sweden. Regional health registers were used as complementary data sources to provide data on positive tests rapidly, and to assess comorbidities and disease outcomes. Comorbidities were defined from diagnoses in inpatient or specialised care at any time point during the 5 years before baseline in the following disease groups (see Supplementary Table S2 for a detailed list): cardiovascular diseases, diabetes or obesity, kidney or liver diseases, respiratory diseases, neurological diseases, cancer or immunosuppressed states, and other conditions and diseases (Down syndrome, HIV, sickle cell anaemia, drug addiction, thalassaemia or mental health disorder). The number of comorbidities in these groupings was counted and used in the analyses. A severe COVID-19 case was defined as at least 24 h hospitalisation 5 days before until 14 days after a positive test and with a need of oxygen supply ≥ 5 L/min or admittance to an intensive care unit (ICU). We used continuous density case-control sampling (6) nested within the study cohort together with conditional logistic regression to estimate vaccine effectiveness (VE) against severe COVID-19. For each severe case, 10 controls without a positive test the same week as the case or 90 days prior were randomly selected from the underlying study cohort, matched with respect to sex and age (five-year groups). Only vaccine doses obtained more than 7 days before the case date were counted in the analyses. BNT16b2 mRNA (Comirnaty, Pfizer-BioNTech) was most frequently used vaccine type with 77% of all administrated doses in the study cohort. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 18, 2022. ; https://doi.org/10.1101/2022.04.14.22273896 doi: medRxiv preprint A total of 593 severe COVID-cases occurred during follow up, corresponding to 65, 78 and 56 cases weekly during the Omicron BA.1, transition and Omicron BA.2 periods, respectively (Table 1) Table 3 ). This decline was consistently noted across subgroups of age, sex and comorbidities. In relative terms, surviving a prior SARS-CoV-2 infection offered stronger protection against new onset of severe COVID-19 among unvaccinated than among vaccinated (Table 2) . However, this protection decreased markedly in both groups during the transition from Omicron BA.1 to BA.2. Ethical approval was obtained from the Swedish Ethical Review Authority (2021-00059). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 18, 2022. ; https://doi.org/10.1101/2022.04.14.22273896 doi: medRxiv preprint A salient finding of the present study was the marked decline in protection against severe COVID-19 during Omicron BA.2 dominance among persons with two vaccine doses only. The decline occurred quite rapidly and thus cannot be explained by waning VE alone. A more likely explanation is increased immune evasiveness properties of BA.2, which gives this genetically subvariant a competitive advantage in highly vaccinated populations (1). The relatively stable protection among individuals with at least three doses during follow up in our study suggests that a very robust immune response is necessary to confer protection also against BA.2. Although the overall vaccination uptake among adults is high (83%) in the study cohort, only 57% had accepted the booster dose that was generally offered to everyone by the end of follow up. We have previously reported substantially lower vaccination uptake in the study cohort among persons born outside the Nordic countries (7). In the current follow up, the overrepresentation of foreign born among cases with severe disease decreased during the transition from BA.1 to BA.2, which points at widespread dropouts from the vaccination program after two doses. This means that the overall population protection against severe COVID-19 can be insufficient in case of new intermittent epidemics that may become the "new normal" (8). Another salient finding was that the protection associated with a prior SARS-CoV-2 infection also declined during the transition from Omicron BA.1 to BA.2. A recent total population study from Sweden reported long-lasting protection among unvaccinated persons who have survived and recovered from a previous SARS-CoV-2 infection (9). However, the follow up of that study ended before Omicron became dominant. Our study with a more recent follow up suggests that the natural protection from previous VOCs against severe disease is markedly lower when Omicron BA.2 is dominant. The key strengths of our study were the detailed individual-level data on vaccinations, . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 18, 2022. ; https://doi.org/10.1101/2022.04.14.22273896 doi: medRxiv preprint infections and hospitalisations and the possibility to stratify hospitalised people further by disease severity, thereby limiting the misclassification of cases hospitalised with rather than because of COVID-19. A major limitation was that we lacked data on virus variant for the individual cases in each time period. Our study may therefore underestimate the true change in VE associated with the transition from BA.1 to BA.2. Another limitation was that we could not evaluate protection from prior Omicron infection, as the follow up period with Omicron dominance is still short. Evidence from Qatar suggests that infection from BA.1 protects against reinfection with BA.2 but this was observed during a very short follow up period (10). A further limitation of our study was that general testing was no longer generally recommended, which means that VE against infection could not be evaluated. It should also be noted that the statistical uncertainty in some of our subgroups were substantial, as reflected in the wide confidence intervals. Continued monitoring of VE associated with Omicron BA.2 is therefore warranted. VE remained relatively stable after the transition from BA.1 to BA.2 among people with at least three doses but decreased markedly among those with only two doses. Protection from prior infection was also lower when BA.2 dominated. These findings suggest that booster vaccination is needed to maintain sufficient protection against severe COVID-19. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 18, 2022. ; https://doi.org/10.1101/2022.04.14.22273896 doi: medRxiv preprint Tables Table 1. Characteristics of the severe COVID-19 cases (N = 593) and sex and age matched controls (N = 5 930), stratified by follow up period for monitoring of vaccine effectiveness. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 18, 2022. ; https://doi.org/10.1101/2022.04.14.22273896 doi: medRxiv preprint Estimates were obtained from conditional logistic regression for age and sex matched case and controls (1:10), and with adjustment for comorbidities (0, 1, ≥2) and infection at least 90 days prior the case date. Results are presented overall and stratified by age, sex and comorbidities. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 18, 2022. ; https://doi.org/10.1101/2022.04.14.22273896 doi: medRxiv preprint B. Two doses . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 18, 2022. ; https://doi.org/10.1101/2022.04.14.22273896 doi: medRxiv preprint Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households. medRxiv COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England. medRxiv Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population -first results from a cohort study in Southern Sweden Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities -surveillance results from southern Sweden